Effects on Glyco-Metabolic Control after 12 Months of Treatment with a Supplement of Ilex Paraguariensis, White Mulberry and Chromium Picolinate in Non-Diabetic Patients with Dysglycemia

Giuseppe Derosa^{1, 2,} , Angela D’Angelo^{1, 3} and Pamela Maffioli^{1, 4}

¹Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy.

²Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy;Centre for Prevention, Surveillance, Diagnosis and Treatment of Dyslipidemia and Atherosclerosis, Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy

³Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy

⁴Centre for Prevention, Surveillance, Diagnosis and Treatment of Dyslipidemia and Atherosclerosis, Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy

Cite this paper:
Giuseppe Derosa, Angela D’Angelo and Pamela Maffioli. Effects on Glyco-Metabolic Control after 12 Months of Treatment with a Supplement of Ilex Paraguariensis, White Mulberry and Chromium Picolinate in Non-Diabetic Patients with Dysglycemia. Journal of Food and Nutrition Research. 2023; 11(4):319-324. doi: 10.12691/jfnr-11-4-6

Abstract

The primary endpoint of the current study was to evaluate whether the effects previously demonstrated in the 3-month study could be maintained for 12 months. Patients were randomized to take Glicoset® in addition to a standardized diet, or to follow a standardized diet alone for 12 months. Glicoset® was self-administered once a day, 1 tablet during the breakfast. After 12 months, 31.9 % of patients retuned to a normal glycemic status in the group treated with nutraceutical + diet vs 3.3 % of patients in diet alone group (p < 0.05). At the end of the study 43.6% were classified as IFG in the group treated with nutraceutical + diet group vs 37% in diet alone group (p < 0.05). In the group treated with nutraceutical + diet, 24.5% were classified as IGT at the end of the study vs 51.1% in diet alone group (p < 0.01). In diet alone group, 8.7% developed type 2 diabetes mellitus vs 0 patients in diet + nutraceutical group (p < 0.05). Total cholesterol, LDL-C, and Tg were lower in the group treated with the nutraceutical combination. The positive effects on glycemic and lipid profile already showed in a 3 months study were also maintained after 12 months of treatment with a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate.

Keywords:
Ilex Paraguariensis White Mulberry Chromium Picolinate

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci 2022; 23(2): 786.
[2]	Gorodeski Baskin R, Alfakara D. Root cause for metabolic syndrome and type 2 diabetes: can lifestyle and nutrition be the answer for remission. Endocrinol Metab Clin North Am 2023; 52(1): 13-25.
[3]	Derosa G, D’Angelo A, Maffioli P. The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature. Phytother Res 2022; 36(10): 3709-3765.
[4]	Derosa G, D’Angelo A, Maffioli P. Metabolic actions of a supplement of Ilex Paraguariensis (an extract of the leaf standardized to 2% I-Deoxinojirimcina), white mulberry and chromium picolinate in nondiabetic subjects with dysglycemia: a randomized trial. Life (Basel) 2021; 11(7): 709.
[5]	Proposed International Guidelines for Biomedical Research Involving Human Subjects. The Council for International Organisation of Medical Sciences. Geneva, 1982.
[6]	Winer BJ. Statistical Principles in Experimental Design. 2nd ed., McGraw-Hill, New York (USA) 1971.
[7]	Derosa G, Cicero AF, D’Angelo A, Borghi C, Maffioli P. Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. Biofactors 2016; 42(3): 316-322.
[8]	de Morais EC, Stefanuto A, Klein GA, Boaventura BC, de Andrade F, Wazlawik E, Di Pietro PF, Maraschin M, da Silva EL. Consumption of yerba mate (Ilex paraguariensis) improves serum lipid parameters in healthy dyslipidemic subjects and provides an additional LDL-cholesterol reduction in individuals on statin therapy. J Agric Food Chem 2009; 57(18): 8316-8324.